C4 Therapeutics

Company snapshot

CD4 Therapeutics is a Munich-based biopharmaceutical company advancing first-in-class immunotherapies to address autoimmune diseases with high unmet medical need. We focus on unlocking the therapeutic potential of regulatory T cells (Tregs) to treat conditions in which conventional biologics are insufficient or fail to provide durable benefit. Building on foundational discoveries in regulatory T c

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 24 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for C4 Therapeutics. Not investment advice.

• Peer + 0 momentum

  Karyopharm Therapeutics

  TA overlap score 36.4

• Peer + 0 momentum

  Alaunos Therapeutics

  TA overlap score 26.8

• Peer + 0 momentum

  Cellectar Biosciences

  TA overlap score 23.4

Recent activity

Latest pipeline, patent, and corporate events for C4 Therapeutics.

1. Jun 5, 2026 Clinical update

   Cemsidomide — Phase 1

2. Jun 5, 2026 Clinical update

   cemsidomide — Phase 2

3. May 23, 2026 Clinical update

   CFT1946 — Phase 1

4. May 23, 2026 Clinical update

   CFT8634 — Phase 1

5. Sep 23, 2025 Patent grant

   Bicyclic-substituted glutarimide cereblon binders

View all clinical trial activity →

• What is C4 Therapeutics?

  C4 Therapeutics is a biotech organization headquartered in WATERTOWN, MA, USA. It trades on NYSE under ticker CCCC. Primary therapeutic focus areas include Multiple Myeloma, Multiple Myeloma (MM), Solid Tumors, Synovial Sarcoma. NovaPharmaNews links 4 clinical program(s), 0 drug

• Is C4 Therapeutics publicly traded?

  Yes. C4 Therapeutics is listed with ticker CCCC on NYSE per SEC EDGAR records linked on this profile.

• What drugs does C4 Therapeutics develop or market?

  We link 1 drug profile(s) where C4 Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/c4-therapeutics#company-drugs.

• What are the latest developments for C4 Therapeutics?

  In the last 12 months our linked public records show 4 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does C4 Therapeutics focus on?

  C4 Therapeutics focuses on Multiple Myeloma, Multiple Myeloma (MM), Solid Tumors based on our analysis of their pipeline programs and drug development activities.